- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Pfizer Ratings Report.
May kicks off with a busy first week filled with earnings, monetary policy and a snapshot of the health of the economy.
The vast majority of U.S. executives surveyed by Ernst & Young have one to three deals already in the works.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.